PROSION Therapeutics is a drug development company based in Cologne & Berlin - Germany. PROSION uses its proprietary ProM-platform technology to unlock highly abundant, yet so far inaccessible PPI-targets mediated by proline-rich-motifs (PRMs). As chemotypes, ProMs are sp3-enriched Proline-mimetics with favorable drug like properties, able combine small molecule PK advantages with protein selectivity of peptide therapeutics.
The lead program in oncology targets a hard-to-drug downstream PPI-target that orchestrates actin remodeling through activation of the Arp2/3 complex. Recent in vivo data in PDAC mouse models show a dual hit effect resulting from treatment with a ProM-based small molecule inhibitor, leading to no detection of the primary tumor ex vivo (full remission) for the majority of mice.
Beyond this program, the ProM Technology can be utilized for further indications within oncology, metabolic, CNS and orphan diseases, as these pathologies mechanistically rely on PRM-mediated interactions as well. As such PROSION Therapeutics is positioned to be the first to unleash their vast therapeutic potential.
The lead program in oncology targets a hard-to-drug downstream PPI-target that orchestrates actin remodeling through activation of the Arp2/3 complex. Recent in vivo data in PDAC mouse models show a dual hit effect resulting from treatment with a ProM-based small molecule inhibitor, leading to no detection of the primary tumor ex vivo (full remission) for the majority of mice.
Beyond this program, the ProM Technology can be utilized for further indications within oncology, metabolic, CNS and orphan diseases, as these pathologies mechanistically rely on PRM-mediated interactions as well. As such PROSION Therapeutics is positioned to be the first to unleash their vast therapeutic potential.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
